The utilisation of cardiac risk ratio and non-HDL cholesterol markers to assess cardiovascular risk in type 2 diabetes males with lowered serum DHT
Keywords:
Dihydrotestosterone, type 2 diabetes mellitus, lipid profile, BMI, cardiac risk ratio, non-HDL cholesterol, cardiovascular diseaseAbstract
Background A risk factor for cardiovascular disease, particularly vascular disease when linked to Diabetes Mellitus, is the decline of male sex androgens. In recent years, many forms of studies have been conducted to confirm its link. Male hypogonadism is linked to dyslipidemia, visceral obesity, and CVD disorders. Testosterone's role in Type 2 Diabetes has been researched alone or in conjunction with Sex hormone binding globulin. DHT, the most recent androgen to be discovered whose functions are being researched and elaborated upon, hasn't received much attention. Very little research has been conducted in India and Asia that looked at androgens associations with cardiac risk indicators. Methods: The study was carried out at Teerthanker Mahaveer Medical College and Research Centre's Department of Physiology and Medicine and Santosh Medical College's Department of Physiology in Moradabad and Ghaziabad, respectively. A total of 210 samples, including 105 from type 2 diabetes and 105 from controls, were used in the investigation. Lipid parameters [HDL, LDL, VLDL & TC], serum DHT, and data analysis were performed using the conventional biochemical methods and SPSS 26 (trial version).
Downloads
References
Jamor P, Ahmadvand H, Birjandi M, Ebadi Sharafabad B. Activity of serum paraoxonase 1, lipid profile and atherogenic indexes in diabetic induced rats treated with alpha lipoic acid. Journal of Nephropathology. 2018;7(4):241–7.
Ukwamedu HA AEM. Assessment of cardiovascular risk indices in type 2 diabetes mellitus. Tropical Medicine & Surgery. 2015;03(02).
Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men. Archives of Internal Medicine. 2001;161(22):2685.
Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. implications for treatment. Circulation. 1992;85(1):37–45.
Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard P-M, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the que´bec cardiovascular study. Circulation. 1996;94(3):273–8.
Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clinic Proceedings. 2015;90(2):224–51.
Chistiakov D, Myasoedova V, Melnichenko A, Grechko A, Orekhov A. Role of androgens in cardiovascular pathology. Vascular Health and Risk Management. 2018;14:283–90.
Karnchanasorn, R., Huang, J., Ou, H.-Y., Feng, W., Chuang, L.-M., Chiu, K. C., & Samoa, R. Comparison of the current diagnostic criterion of hba1c with fasting and 2-hour plasma glucose concentration. Journal of Diabetes Research. 2016; 1–11. https://doi.org/10.1155/2016/6195494
Dhariwala, M. Y., & Ravikumar, P. (2019). An overview of herbal alternatives in androgenetic alopecia. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.12930
Swerdloff, R. S., Dudley, R. E., Page, S. T., Wang, C., & Salameh, W. A. (2017). Dihydrotestosterone: Biochemistry, physiology, and clinical implications of elevated blood levels. Endocrine Reviews, 38(3), 220–254. https://doi.org/10.1210/er.2016-1067 .
AMBADE VIVEKN, SHARMA YV, SOMANI BL. Methods for estimation of blood glucose : A comparative evaluation. Medical Journal Armed Forces India. 1998;54(2):131–3.
Slowinska-Solnica K, Pawlica-Gosiewska D, Gawlik K, Kuzniewski M, Maziarz B, Solnica B. Boronate affinity chromatography accurately measures hba1c also in patients with end-stage renal disease - performance evaluation of the A1C HPLC analyzer. Clinical Laboratory. 2018;64(09/2018).
Biotec-co.com. [cited 2022 Jun 30]. Available from: https://www.biotec-co.com/images/products/clinical_chemistry/kits/chemistry/Cholesterol.pdf
Adveetabiotech.com. [cited 2022 Jun 30]. Available from: https://adveetabiotech.com/wp-content/uploads/2020/05/21_Triglycerides-_Test_Kit.pdf
HDL Cholesterol precipitating reagent set [Internet]. Biopacific.net. [cited 2022 Jun 30]. Available from: http://www.biopacific.net/wp-content/uploads/2016/07/Pointe-HDL-Cholesterol-PEG-Insert.pdf
Krishnaveni P, Gowda VM. Assessing the validity of Friedewald’s Formula and anandraja’s formula for serum LDL-cholesterol calculation. J Clin Diagn Res [Internet]. 2015;9(12):BC01-4. Available from: http://dx.doi.org/10.7860/JCDR/2015/16850.6870.
Biosciences E. Dihydrotestosterone (DHT) ELISA Assay Kit [Internet]. Eaglebio.com. [cited 2022 Jun 30]. Available from: https://eaglebio.com/wp-content/uploads/data-pdf/dht31-dht-elisa-assay-kit-packageinsert.pdf.
U.S. National Library of Medicine. (n.d.). Home - books - NCBI. National Center for Biotechnology Information. Retrieved July 12, 2022, from https://www.ncbi.nlm.nih.gov/books
Wynne, F. L., & Khalil, R. A. (2003). Testosterone and coronary vascular tone: Implications in coronary artery disease. Journal of Endocrinological Investigation, 26(2), 181–186. https://doi.org/10.1007/bf03345150
Marrachelli, V. G., Miranda, F. J., Centeno, J. M., Salom, J. B., Torregrosa, G., Jover-Mengual, T., Pérez, A. M., Moro, M. A., & Alborch, E. (2010). Role of no-synthases and cyclooxygenases in the hyperreactivity of male rabbit carotid artery to testosterone under experimental diabetes. Pharmacological Research, 61(1), 62–70. https://doi.org/10.1016/j.phrs.2009.06.008
Norata, G. D., Tibolla, G., Seccomandi, P. M., Poletti, A., & Catapano, A. L. (2006). Dihydrotestosterone decreases tumor necrosis factor-α and lipopolysaccharide-induced inflammatory response in human endothelial cells. The Journal of Clinical Endocrinology & Metabolism, 91(2), 546–554. https://doi.org/10.1210/jc.2005-1664
Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of Body Mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiology. 2018;3(4):280–7.
Zhao Y, Qie R, Han M, Huang S, Wu X, Zhang Y, et al. Association of BMI with cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus: A systematic review and dose–response meta-analysis of Cohort studies. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31(7):1976–84.
Peters SA, Bots SH, Woodward M. Sex differences in the association between measures of general and central adiposity and the risk of myocardial infarction: Results from the UK Biobank. Journal of the American Heart Association. 2018;7(5).
Murray S. Is waist-to-hip ratio a better marker of cardiovascular risk than body mass index? Canadian Medical Association Journal. 2006;174(3):308–.
Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Localization of fat depots and cardiovascular risk. Lipids in Health and Disease. 2018;17(1):218.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143-3143.
Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia. 2000;43(2):148-155.
Vasanthakumar J, Kambar S. Prevalence of obesity among type 2 diabetes mellitus patients in urban areas of Belagavi. Indian Journal of Health Sciences and Biomedical Research (KLEU). 2020;13(1):21.
Unnikrishnan A, Kalyan M, Dhore P, Purandare V, Deshpande S. Obesity and its link to undiagnosed diabetes mellitus and hypertension in rural parts of western India. Indian Journal of Endocrinology and Metabolism. 2020;24(2):155.
Tandon N, Anjana R, Mohan V, Kaur T, Afshin A, Ong K et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. The Lancet Global Health. 2018;6(12):e1352-e1362.
Pandya H, Lakhani JD, Dadhania J, Trivedi A. The prevalence and pattern of dyslipidemia among type 2 diabetic patients at rural based hospital in Gujarat, India. Indian J Clinic Pract. 2012;22(12):36-44.
Tagoe DN, Amo-Kodieh P. Type 2 diabetes mellitus influences lipid profile of diabetic patients. Annals Bio Res. 2013;4(6):88-92.
Jayarama N, Reddy M, Raj SD. Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, southern India. Glob J Med Public Health. 2012;1:24-8.
Joyce K, Biggs M, Djoussé L, Ix J, Kizer J, Siscovick D et al. Testosterone, Dihydrotestosterone, Sex Hormone Binding Globulin and Incident Diabetes among Older Men: the Cardiovascular Health Study. The Journal of Clinical Endocrinology & Metabolism. 2016;:jc.2016-2623.
Mather K, Kim C, Christophi C, Aroda V, Knowler W, Edelstein S et al. Steroid Sex Hormones, Sex Hormone–Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program. The Journal of Clinical Endocrinology & Metabolism. 2015;100(10):3778-3786.
Vandenput L, Mellström D, Lorentzon M, Swanson C, Karlsson M, Brandberg J et al. Androgens and Glucuronidated Androgen Metabolites Are Associated with Metabolic Risk Factors in Men. The Journal of Clinical Endocrinology & Metabolism. 2007;92(11):4130-4137.
Salcedo-Cifuentes M, Belalcazar S, Acosta E, Medina-Murillo J. Conventional biomarkers for cardiovascular risks and their correlation with the castelli risk index-indices and tg/hdl-c. Archivos de Medicina (Manizales). 2019;20(1):11-22.
Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ; 2003;169(9):921-924.
Brunner F, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. The Lancet. 2019;394(10215):2173-2183.
Pencina K, Thanassoulis G, Wilkins J, Vasan R, Navar A, Peterson E et al. Trajectories of Non–HDL Cholesterol Across Midlife. Journal of the American College of Cardiology. 2019;74(1):70-79.
Yeap B, Alfonso H, Chubb S, Handelsman D, Hankey G, Almeida O et al. In Older Men an Optimal Plasma Testosterone Is Associated With Reduced All-Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality. The Journal of Clinical Endocrinology & Metabolism. 2014;99(1):E9-E18.
Wu F, von Eckardstein A. Androgens and Coronary Artery Disease. Endocrine Reviews. 2003;24(2):183-217.
Norata G, Tibolla G, Seccomandi P, Poletti A, Catapano A. Tu-P7:120 Dihydrotestosterone decreases tumor necrosis factor A and lipopolysaccharide induced inflammatory response in human endothelial cells. Atherosclerosis Supplements. 2006;7(3):211.
Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids in Health and Disease. 2019;18(1).
Bittner V, Bertolet M, Barraza Felix R, Farkouh M, Goldberg S, Ramanathan K et al. Comprehensive Cardiovascular Risk Factor Control Improves Survival. Journal of the American College of Cardiology. 2015;66(7):765-773.
Biochemistry, high density lipoprotein - NCBI bookshelf [Internet]. StatPearls. [cited 2022Jul16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549802/
Making sense of cholesterol tests [Internet]. Harvard Health. 2022 [cited 2022Jul16]. Available from: https://www.health.harvard.edu/heart-health/making-sense-of-cholesterol-tests
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
